Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA in Sepsis
NCT07852780Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Oct 2026
- Primary completion
- Oct 2027
01
Overview
Phase 3, randomised, open-label trial of ursodeoxycholic acid in sepsis (2 arms), sponsored by Tanta University. Primary endpoint: Absolute change in serum MDA concentration at day 5. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07852780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852780.